Edison Goncalves
Research Subjects
Edison Goncalves has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- David Samuel Henry Bell
Southside Endocrinology Birmingham Alabama USA
7 shared publications David S. H. Bell
Southside Endocrinology, Irondale, USA
2 shared publicationsDavid S.H. Bell
Southside Endocrinology, Diabetes and Thyroid Associates, Birmingham, AL, United States
2 shared publications- David Bell
Centre for Synthetic Biology Imperial College London London UK
1 shared publication - Izabel Fernanda Machado
Surface Phenomena Laboratory, LFS, University of São Paulo, São Paulo 05508-030, Brazil
1 shared publication Nelson O. Cárdenas
Polytechnic School University of São Paulo
1 shared publication
Latest Publications
- Open Access
- 19 August 2021
- Published by Springer Nature in Diabetes Therapy
- Vol. 12 (10) , 2631-2634
Alcohol Consumption as a Causator and/or an Accelerator of Neuropathy in People With Diabetes Is Regularly Overlooked
Patients with diabetes and distal symmetrical polyneuropathy (DSP) are routinely evaluated for etiologies other than diabetes, including vitamin B12 deficiency, paraproteinemia, hypothyroidism and drug or autoimmune-induced neuropathy. However, the most common cause of DSP, next to that of diabetes, is alcohol intake, which is almost never evaluated. In addition to assessment of alcohol intake based on patient history, which often leads to an underestimation of alchohol intake, markers of a high alcohol intake (elevated liver enzymes, uric acid, triglycerides, low magnesium or low folic acid levels) should be obtained. However, the test that is most likely to detect surreptitious alcohol intake is urinary ethyl glucuronide (EtG), which will detect the intake of alcohol within the previous 90 h. Detection of alcohol use is important since if alcohol consumption is not discontinued, DSP, whatever the etiology, will not improve. In addition, the use of drugs to improve symptoms of DSP (tricyclics, anti-epileptics, serotonin, norepinephrine reuptake inhibitors and analgesics) may in combination with alcohol excessively suppress respiration and cognitive function such that these drugs should not be prescribed or utilized if use of alcohol continues. In the future, all patients with DSP, and especially those with symptomatic DSP, should be biochemically screened for excessive alcohol intake and appropriate action taken.
- 19 August 2021
- Published by Springer Nature in Diabetes Therapy
- Vol. 12 (10) , 2631-2634
Open AccessAlcohol Consumption as a Causator and/or an Accelerator of Neuropathy in People With Diabetes Is Regularly Overlooked
Patients with diabetes and distal symmetrical polyneuropathy (DSP) are routinely evaluated for etiologies other than diabetes, including vitamin B12 deficiency, paraproteinemia, hypothyroidism and drug or autoimmune-induced neuropathy. However, the most common cause of DSP, next to that of diabetes, is alcohol intake, which is almost never evaluated. In addition to assessment of alcohol intake based on patient history, which often leads to an underestimation of alchohol intake, markers of a high alcohol intake (elevated liver enzymes, uric acid, triglycerides, low magnesium or low folic acid levels) should be obtained. However, the test that is most likely to detect surreptitious alcohol intake is urinary ethyl glucuronide (EtG), which will detect the intake of alcohol within the previous 90 h. Detection of alcohol use is important since if alcohol consumption is not discontinued, DSP, whatever the etiology, will not improve. In addition, the use of drugs to improve symptoms of DSP (tricyclics, anti-epileptics, serotonin, norepinephrine reuptake inhibitors and analgesics) may in combination with alcohol excessively suppress respiration and cognitive function such that these drugs should not be prescribed or utilized if use of alcohol continues. In the future, all patients with DSP, and especially those with symptomatic DSP, should be biochemically screened for excessive alcohol intake and appropriate action taken.
- Open Access
- 1 January 2021
- Published by Frontiers in Medical Case Reports in Frontiers in Medical Case Reports
- Vol. 02 (03)
Are There Differences in Potency Between SGLT-2 Receptor Blockers Utilized in The Therapy of Heart Failure?
- 1 January 2021
- Published by Frontiers in Medical Case Reports in Frontiers in Medical Case Reports
- Vol. 02 (03)
Open AccessAre There Differences in Potency Between SGLT-2 Receptor Blockers Utilized in The Therapy of Heart Failure?
- 15 December 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (4) , 877-885
Diabetogenic effects of cardioprotective drugs
Drugs that protect against cardiovascular events in the patient with diabetes may also positively or negatively affect glycaemic control in the patient with established diabetes and may induce the development of diabetes in the predisposed patient. Mainly through increasing insulin resistance, beta‐blockers, statins and high‐dose diuretics have the potential to worsen glycaemic control. Dihydropyridine calcium channel blockers, low‐dose diuretics, vasodilating beta‐blockers, alpha‐blockers and pitavastatin have little or no effect on glycaemic control. Blockers of the renin‐angiotensin‐aldosterone system, colesevelam, ranolazine and verapamil, through slowing breakdown of bradykinin, vasodilation, increasing cholecystokinin levels, blocking sodium channels and decreasing beta cell apoptosis, may improve glycaemic control and avoid the development of diabetes.
- 15 December 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (4) , 877-885
Diabetogenic effects of cardioprotective drugs
Drugs that protect against cardiovascular events in the patient with diabetes may also positively or negatively affect glycaemic control in the patient with established diabetes and may induce the development of diabetes in the predisposed patient. Mainly through increasing insulin resistance, beta‐blockers, statins and high‐dose diuretics have the potential to worsen glycaemic control. Dihydropyridine calcium channel blockers, low‐dose diuretics, vasodilating beta‐blockers, alpha‐blockers and pitavastatin have little or no effect on glycaemic control. Blockers of the renin‐angiotensin‐aldosterone system, colesevelam, ranolazine and verapamil, through slowing breakdown of bradykinin, vasodilation, increasing cholecystokinin levels, blocking sodium channels and decreasing beta cell apoptosis, may improve glycaemic control and avoid the development of diabetes.
- 1 November 2020
- Published by Elsevier in Diabetes & Metabolism
- Vol. 46 (6) , 515-517
Efficacy of semaglutide versus liraglutide in clinical practice
- 1 November 2020
- Published by Elsevier in Diabetes & Metabolism
- Vol. 46 (6) , 515-517
Efficacy of semaglutide versus liraglutide in clinical practice
- 1 June 2020
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 164, 108193
Stroke in the patient with diabetes (part 1) – Epidemiology, etiology, therapy and prognosis
- 1 June 2020
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 164, 108193
Stroke in the patient with diabetes (part 1) – Epidemiology, etiology, therapy and prognosis
- 12 May 2020
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 164, 108199
Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies
- 12 May 2020
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 164, 108199
Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies
- 5 February 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (6) , 1277-1290
Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications
In people with type 2 diabetes the frequency of heart failure (HF) is increased and mortality from HF is higher than with non‐diabetic HF. The increased frequency of HF is attributable to the cardiotoxic tetrad of ischaemic heart disease, left ventricular hypertrophy, diabetic cardiomyopathy and an extracellular volume expansion resistant to atrial natriuretic peptides. Activation of the renin‐angiotensin‐aldosterone system and sympathetic nervous systems results in cardiac remodelling, which worsens cardiac function. Reversal of remodelling can be achieved, and cardiac function improved in people with HF with reduced ejection fraction (HFrEF) by treatment with angiotensin‐converting enzyme inhibitors and β‐blockers. However, with HF with preserved ejection fraction (HFpEF), only therapy for the underlying risk factors helps. Blockers of mineralocorticoid receptors may be beneficial in both HFrEF and HFpEF. Glucose‐lowering drugs can have a negative effect (insulin, sulphonylureas, dipeptidyl peptidase‐4 inhibitors and thiazolidinediones), a neutral effect (α‐glucosidase inhibitors and glucagon‐like peptide‐1 receptor agonists) or a positive effect (sodium‐glucose co‐transporter‐2 inhibitors and metformin).
- 5 February 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (6) , 1277-1290
Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications
In people with type 2 diabetes the frequency of heart failure (HF) is increased and mortality from HF is higher than with non‐diabetic HF. The increased frequency of HF is attributable to the cardiotoxic tetrad of ischaemic heart disease, left ventricular hypertrophy, diabetic cardiomyopathy and an extracellular volume expansion resistant to atrial natriuretic peptides. Activation of the renin‐angiotensin‐aldosterone system and sympathetic nervous systems results in cardiac remodelling, which worsens cardiac function. Reversal of remodelling can be achieved, and cardiac function improved in people with HF with reduced ejection fraction (HFrEF) by treatment with angiotensin‐converting enzyme inhibitors and β‐blockers. However, with HF with preserved ejection fraction (HFpEF), only therapy for the underlying risk factors helps. Blockers of mineralocorticoid receptors may be beneficial in both HFrEF and HFpEF. Glucose‐lowering drugs can have a negative effect (insulin, sulphonylureas, dipeptidyl peptidase‐4 inhibitors and thiazolidinediones), a neutral effect (α‐glucosidase inhibitors and glucagon‐like peptide‐1 receptor agonists) or a positive effect (sodium‐glucose co‐transporter‐2 inhibitors and metformin).
- Open Access
- 24 August 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (2) , 210-217
Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapies
New‐onset atrial fibrillation (NAF) is increased in the type 2 diabetic patient because of the presence of the metaboli syndrome and increased sympathetic activity. This results in inflammation, endothelial dysfunction and myocardial steatosis which, in turn, lead to atrial fibrosis and dilatation. The end result is the development of structural and electrical atrial remodeling. Drugs that lower insulin resistance, particularly pioglitazone, decrease the incidence of NAF while drugs that, through hypoglycaemia, stimulate the sympathetic nervous system, insulin and secretagogues, increase the incidence of NAF. Currently there is no evidence that GLP‐1 agonists, SGLT2 inhibitors and DPP‐4 inhibitors either accelerate or decelerate the development of NAF.
- 24 August 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (2) , 210-217
Open AccessAtrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapies
New‐onset atrial fibrillation (NAF) is increased in the type 2 diabetic patient because of the presence of the metaboli syndrome and increased sympathetic activity. This results in inflammation, endothelial dysfunction and myocardial steatosis which, in turn, lead to atrial fibrosis and dilatation. The end result is the development of structural and electrical atrial remodeling. Drugs that lower insulin resistance, particularly pioglitazone, decrease the incidence of NAF while drugs that, through hypoglycaemia, stimulate the sympathetic nervous system, insulin and secretagogues, increase the incidence of NAF. Currently there is no evidence that GLP‐1 agonists, SGLT2 inhibitors and DPP‐4 inhibitors either accelerate or decelerate the development of NAF.
- 8 June 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (10) , 2510-2511
Increase in glycated haemoglobin concentrations after unwarranted prescription changes
- 8 June 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (10) , 2510-2511
Increase in glycated haemoglobin concentrations after unwarranted prescription changes
- 22 May 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (10) , 2327-2329
Should we still be utilizing warfarin in the type 2 diabetic patient?
The frequency of non‐valvular atrial fibrillation is increased by 40% in type 2 diabetic individuals and the thromboembolic risk associated with atrial fibrillation is increased by 79% compared with the non‐diabetic individual with atrial fibrillation. Warfarin, the traditional anticoagulant used to prevent thromboembolism, is non‐specific and affects several proteins outside the coagulation system. Decreasing the levels of matrix Gla protein entails an increase in coronary and renal artery calcification, which has the potential to increase cardiovascular events and accelerate decline in renal function. The direct‐acting oral anticoagulants are specific, directly inhibiting either thrombin or factor Xa, and have been shown to be safer and more efficacious in studies of the type 2 diabetic patient.
- 22 May 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (10) , 2327-2329
Should we still be utilizing warfarin in the type 2 diabetic patient?
The frequency of non‐valvular atrial fibrillation is increased by 40% in type 2 diabetic individuals and the thromboembolic risk associated with atrial fibrillation is increased by 79% compared with the non‐diabetic individual with atrial fibrillation. Warfarin, the traditional anticoagulant used to prevent thromboembolism, is non‐specific and affects several proteins outside the coagulation system. Decreasing the levels of matrix Gla protein entails an increase in coronary and renal artery calcification, which has the potential to increase cardiovascular events and accelerate decline in renal function. The direct‐acting oral anticoagulants are specific, directly inhibiting either thrombin or factor Xa, and have been shown to be safer and more efficacious in studies of the type 2 diabetic patient.